Shanghai Junshi Biosciences Co., Ltd. Class A

As of December 31, 2025, Shanghai Junshi Biosciences Co., Ltd. Class A carries a market capitalization of 35.04B, placing it among publicly traded companies globally. Its enterprise value stands at 36.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Junshi Biosciences Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of December 31, 2025, Shanghai Junshi Biosciences Co., Ltd. Class A has 1.03B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Shanghai Junshi Biosciences Co., Ltd. Class A maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Shanghai Junshi Biosciences Co., Ltd. Class A's stock has declined approximately 15.52% over the past 52 weeks. The 50-day moving average sits at 34.32, while the 200-day moving average is 35.40.

As of December 31, 2025, Shanghai Junshi Biosciences Co., Ltd. Class A holds 3.19B in cash and equivalents against 4.14B in total debt, resulting in a net debt position of 1.46B. Total book value stands at 6.05B, with working capital of 1.65B providing operational flexibility.